雷贝拉唑减少急性心肌梗死患者术后消化道出血的疗效观察

The clinical efficacy of rabeprazole in reducing postoperative gastrointestinal bleeding in patients with acute myocardial infarction

分析雷贝拉唑应用于减少急性心肌梗死患者术后消化道出血的临床效果。方法 选取本院收治的确诊为急性心肌梗死患者88例，所有患者均行经皮冠状动脉介入治疗。将患者按照用药方法分为观察组与对照组，对照组44例采用阿司匹林联合替格瑞洛治疗；观察组44例在对照组的基础上采用雷贝拉唑进行治疗。观察两组术后4周消化道出血的发生情况，并对比两组治疗前后不同时点的PLT、Hb及RBC的变化情况，比较两组用药不良反应。结果 术后4周内，观察组患者消化道出血的总发生率明显较对照组低（P＜0.05）；观察组术后2、4周的PLT、Hb水平及RBC均显著高于对照组，两组比较差异有统计学意义（P＜0.05）；两组患者用药后不良反应的发生率比较差异无统计学意义（P＞0.05）。结论 运用雷贝拉唑可显著减少急性心肌梗死患者行经皮冠状动脉介入治疗术后消化道出血的发生，且不良反应较少，值得临床推广应用。

To investigate and analyze the clinical effect of rabeprazole in reducing postoperative gastrointestinal bleeding in patients with acute myocardial infarction.Methods Eighty-eight patients diagnosed as acute myocardial infarction admitted to our hospital were enrolled in this study.All patients underwent percutaneous coronary intervention.The patients were divided into observation group and control group according to the method of treatment.44 cases in the control group were treated with aspirin combined with ticagrelor,44 cases in the observation group were treated with rabeprazole on the basis of the control group.The incidence of gastrointestinal bleeding at 4 weeks after operation was observed.The changes of PLT,Hb,and RBC at different time points before and after treatment were compared between two groups.Adverse reactions were compared between the two groups.Results The incidence of gastrointestinal bleeding within 4 weeks after operation in the observation group was significantly lower than that in the control group(P<0.05).The levels of PLT,Hb,and RBC in the observation group at 2 and 4 weeks after operation were significantly higher than those in the control group,with statistically significant differences between the two groups(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of rabeprazole can significantly reduce the incidence of gastrointestinal bleeding after percutaneous coronary intervention in patients with acute myocardial infarction,with fewer adverse reactions in patients,worthy of clinical application.